Opinion Review
Copyright ©The Author(s) 2025.
World J Hepatol. Feb 27, 2025; 17(2): 99809
Published online Feb 27, 2025. doi: 10.4254/wjh.v17.i2.99809
Table 1 Key points concerning transjugular intrahepatic portosystemic shunt
Technical aspectsPerform TIPS with anesthetic sedation or general anesthesia
Use prosthesis coated with PTFE
Measure HVPG
Puncture the portal vein branch guided by abdominal ultrasound
Use preferably a prosthesis of 8 mm
Monitoring patients to assess TIPS patency, with doppler ultrasound performed at 1 week, 3 months, 6 months and then every 6 months
IndicationsRefractory ascites
Recurrent ascites that are difficult to manage
Variceal bleeding unresponsive to pharmacological treatment combined with endoscopic therapy
Variceal rebleeding in the first 5 days
High risk for rebleeding (pTIPS): Child C score < 14 points or Child B with a score > 7 with active bleeding on endoscopy, in the first 72 hours after combined treatment (endoscopic and vasoactive drugs), regardless of whether they responded to initial standard therapy
Hepatic hydrothorax
Budd-Chiari syndrome
Portosinusoidal vascular disorder
Hepatorenal syndrome not associated with AKI
To prevent future decompensation in cirrhosis
Contraindications Absolute: Severe uncontrolled HE, systemic infection or sepsis, congestive heart failure (stage C or D, or a documented ejection fraction < 50%); severe pulmonary arterial hypertension, untreated biliary obstruction
Relative: Very high MELD score, Child-Pugh score > 13 points, severe coagulopathy, polycystic liver disease, portal or hepatic vein occlusion and intrahepatic tumors
Complications HE, deterioration of liver function and complications related to cardiac overload (low-risk if BNP < 40 pg/mL; NT-proBNP < 125 pg/mL; absence of a prolonged QT interval and diastolic dysfunction criteria on the echocardiogram)